We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Simple Blood Sample to Diagnose TBI Severity Could Reduce Need for MRI Scan

By LabMedica International staff writers
Posted on 11 May 2022

Traumatic brain injury (TBI) is one of the most common neurological diseases worldwide affecting all ages and is commonly caused by a fall, road traffic accident or assault. More...

TBI is divided into three categories ranging from mild to severe, although no reliable methods exist for ruling out acute brain injury. Researchers have now identified biomarkers in the blood that can indicate how serious a head trauma is, enabling a simple blood sample to diagnose TBI severity.

Researchers at Örebro University (Örebro, Sweden) who have been working on a non-surgical procedure to diagnose TBI severity used blood samples collected by EU project CENTER-TBI - the largest study of its kind. The EU project CENTER-TBI currently prospectively collects clinical data including records from 5,400 patients, files of imaging workup as well as blood samples from TBI patients from 60 sites of 18 countries. The overall objective is to apply metabolic profiling of serum in the CENTER-TBI cohort to study the utility of the existing as well as to identify novel biomarkers of TBI which are also predictive of patient outcomes.

Using metabolomics - a chemical analysis method to extract information about thousands of small molecules - the Örebro researchers have identified biomarkers that can be linked to TBI. With the help of these biomarkers, healthcare providers will not only be able to assess the severity of the injury but also predict the patient outcome. Healthcare providers will be able to categorize the injuries more clearly by simply taking a blood sample which is cost-effective, simpler and safer for the patient and eliminates the need for an MRI scan.

Related Links:
Örebro University 


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.